Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia-Reference-Cited by-同舟云学术

Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia

Published:2018-03 Issue:3 Volume:38 Page:481-483
ISSN:1079-5642
Container-title:Arteriosclerosis, Thrombosis, and Vascular Biology
language:en
Short-container-title:Arterioscler Thromb Vasc Biol.

Author:

Santos Raul D.¹

Affiliation:

1. From the Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Brazil; and Preventive Medicine Centre and Cardiology Program, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference19 articles.

1. Familial hypercholesterolaemia

2. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

3. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations

4. Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia

5. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evinacumab: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2024-06

2. Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies;Annals of Medicine & Surgery;2024-03-12

3. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial;Circulation;2024-01-30

4. LDL-C–Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes;Circulation;2024-01-30

5. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia;Circulation;2024-01-30